Gilead Sciences to buy Triangle Pharmaceuticals
BY Advocate.com Editors
December 07 2002 12:00 AM ET
Gilead Sciences, the maker of HIV nucleotide reverse transcriptase inhibitor Viread, has agreed to buy Triangle Pharmaceuticals, which has one HIV and two hepatitis treatments in development, for $464 million, the Raleigh [N.C.] News and Observer reports. Among Triangle's products in development is the anti-HIV nucleoside reverse transcriptase inhibitor Coviricil, which is expected to receive Food and Drug Administration approval in early 2003.
Mark Perry, Gilead's chief operating officer, says the companies plan to develop a combined, once-a-day tablet that includes both Viread and Coviricil. "Both products are very strong, once-a-day products that are very safe and effective individually," he said. "We think the combined product will be an outstanding product." The sale still must be approved by Gilead shareholders, but because the company's board controls 41% of Gilead's stock, approval is virtually guaranteed.
- Women WATCH: Real-Life Girlfriends Bria & Chrissy on '10 Things Lesbians Do on Saturdays' 2 min 1 sec ago
- Travel Stockholm Pride Sent an FU to Putin 13 min 23 sec ago
- Sports WATCH: Sportscaster Denies Calling Kansas Jayhawks 'Gayhawks' 43 min 43 sec ago
- Music 6 New Christmas Albums To Get You In the Holiday Mood 1 hour 10 min ago
- Film George Takei Documentary to Premiere at Sundance 1 hour 12 min ago
- World News WATCH: Obama Invokes LGBT Rights in Mandela Eulogy 1 hour 19 min ago
- Crime Gay Man Allegedly Assaulted by Hasidic Gang in New York 1 hour 30 min ago